SCHEMBL208703

SCHEMBL208703

Cc1ccc(C(=O)S(=O)(=O)CCOC=O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.39
ALDH1A1 P00352 4/20 0.39
PKM P14618 2/20 0.39
HTT P42858 2/20 0.39
ATM Q13315 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
LMNA P02545 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
NLRP1 Q9C000 1/20 0.39
MEN1 O00255 1/20 0.39
NTSR1 P30989 1/20 0.39
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
GAA P10253 1/20 0.37
GSK3B P49841 1/20 0.37
HSD11B1 P28845 1/20 0.36
PAX8 Q06710 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL208702 0.79 ALDH1A1 (0.37) KMT2AALDH1A1PKMHTTATM
SCHEMBL777046 0.75 ALDH1A1 (0.50) KMT2AALDH1A1PKMHTTATM
SCHEMBL64437 0.73 ALDH1A1 (0.60) KMT2AALDH1A1HTTLMNASMN1; SMN2
SCHEMBL22022744 0.72 LMNA (0.47) KMT2AALDH1A1NPSR1LMNATDP1
SCHEMBL3626577 0.71 ALDH1A1 (0.42) KMT2AALDH1A1PKMHTTATM
SCHEMBL17702639 0.70 NPC1 (0.53) KMT2AALDH1A1PKMHTTATM
SCHEMBL15927322 0.70 NPC1 (0.51) ALDH1A1LMNATDP1SMN1; SMN2GAA
SCHEMBL9312379 0.69 ALDH1A1 (0.43) KMT2AALDH1A1PKMHTTATM
SCHEMBL21247965 0.69 KMT2A (0.44) KMT2AALDH1A1PKMHTTATM
SCHEMBL180685 0.68 ALDH1A1 (0.56) KMT2AALDH1A1PKMHTTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107162928-B Halogenated analogs of anti-fibrotic agents 塞尔塔医疗有限公司 2022-03-11 CN disclosed
US-10814013-B2 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-10-27 US disclosed
US-9265739-B2 Methods and use of compounds that bind to HER2/neu receptor complex THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-02-23 US disclosed
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-8993634-B2 Methods and use of compounds that bind to Her2/neu receptor complex THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2015-03-31 US disclosed
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-8758723-B2 Compositions and methods for cellular imaging and therapy THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-06-24 US disclosed
US-8703980-B2 Process for the preparation of darunavir TIANISH LABORATORIES PRIVATE LIMITED (IN) 2014-04-22 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
US-20080119512-A1 Carboxamide Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2008-05-22 US disclosed
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-05-22 US disclosed
US-20080096942-A1 Substituted Hydroxyethylamines ELAN PHARMACEUTICALS, INC. 2008-04-24 US disclosed
US-20080058336-A1 Methods to Treat Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2008-03-06 US disclosed
US-20070299263-A1 Hydroxy Alkyl Amines Elan Pharmaceuticals, Inc. and Pharmacia & Upjohn Company 2007-12-27 US disclosed
US-20070275910-A1 Phosphoramidate Derivatives UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2007-11-29 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed
US-20070248537-A1 Compositions and Methods for Cellular Imaging and Therapy THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2007-10-25 US disclosed
US-20070225374-A1 Hydroxypropyl Amides for the Treatment of Alzheimer's Disease ELAN PHARMACEUTICALS, INC. (US) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096942-A1 Substituted Hydroxyethylamines BACE1, BACE2, MME KMT2A 528/4885ALDH1A1 2044/4885PKM 3036/4885
US-10814013-B2 Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications TNNI3, CAD, TNNT2 KMT2A 1922/4885ALDH1A1 2581/4885PKM 2869/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A KMT2A 4447/4885ALDH1A1 4835/4885PKM 4767/4885
US-20080058336-A1 Methods to Treat Alzheimer's Disease PSEN2, PSEN1, ACHE KMT2A 1781/4885ALDH1A1 412/4885PKM 1886/4885
US-20080119455-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 KMT2A 1526/4885ALDH1A1 192/4885PKM 70/4885
US-20070299263-A1 Hydroxy Alkyl Amines MAOA, PSEN2, PSEN1 KMT2A 1229/4885ALDH1A1 597/4885PKM 2039/4885
US-20070275910-A1 Phosphoramidate Derivatives HRH4, HRH3, NR1H4 KMT2A 2517/4885ALDH1A1 3963/4885PKM 2168/4885
US-20080119512-A1 Carboxamide Derivatives as Therapeutic Agents AGER, S100B, S100A4 KMT2A 4158/4885ALDH1A1 2785/4885PKM 1805/4885
US-20070248537-A1 Compositions and Methods for Cellular Imaging and Therapy H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCL, NME4 KMT2A 4475/4885ALDH1A1 4432/4885PKM 2273/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP KMT2A 4094/4885ALDH1A1 1717/4885PKM 3404/4885
US-20070225374-A1 Hydroxypropyl Amides for the Treatment of Alzheimer's Disease BACE1, APP, BACE2 KMT2A 2692/4885ALDH1A1 800/4885PKM 3215/4885
US-20080119454-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 KMT2A 1526/4885ALDH1A1 192/4885PKM 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.